Array BioPharma Inc.

Belkins
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

LEO LENS PHARMA EXCITED TO HAVE ITS LEAD ASSET READY FOR HUMAN CLINICAL EVALUATION

Leo Lens Pharma | June 23, 2020

news image

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clini...

Read More

ABBVIE, AMGEN AND TAKEDA TAKE COLLABORATIVE EFFORTS TO TACKLE COVID-19

Fiercepharma | August 03, 2020

news image

The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to see whether their products can improve outcomes for severely ill patients. A recently launched clinical program, dubbed I-SPY, will test Amgen’s psoriasis med Otezla, Takeda’s hereditary angioedema therapy Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc to s...

Read More

RESEARCH

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma | November 30, 2020

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

CHALLENGES FOR TRANSLATING PHARMACOMICROBIOMICS TO PERSONALIZED MEDICINE

News-Medical.Net | March 02, 2020

news image

A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.Pharmacomicrobiomics is the study of how microbiome variations within and between individuals affect drug action, efficacy, and toxicity. This personalized medicine horizon scanning is featured in OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. Ramy Aziz and Marwa ElRakaiby, Cairo Univer...

Read More

Leo Lens Pharma | June 23, 2020

news image

LEO LENS PHARMA EXCITED TO HAVE ITS LEAD ASSET READY FOR HUMAN CLINICAL EVALUATION

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clini...

Read More

Fiercepharma | August 03, 2020

news image

ABBVIE, AMGEN AND TAKEDA TAKE COLLABORATIVE EFFORTS TO TACKLE COVID-19

The drug industry has come together in unprecedented collaborative efforts to tackle COVID-19. Now, as part of an R&D alliance, three big drugmakers are running a joint clinical trial to see whether their products can improve outcomes for severely ill patients. A recently launched clinical program, dubbed I-SPY, will test Amgen’s psoriasis med Otezla, Takeda’s hereditary angioedema therapy Firazyr and AbbVie’s experimental nonalcoholic steatohepatitis drug cenicriviroc to s...

Read More

RESEARCH

Ascentage Pharma | November 30, 2020

news image

ASCENTAGE PHARMA ENTERS INTO AN AGREEMENT WITH UNIVERSITY OF MICHIGAN TO OBTAIN AN EXCLUSIVE LICENSE FOR DEGRADER

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignant growths, ongoing hepatitis B (CHB), and age-related infections, today reported it has gone into a concurrence with the University of Michigan, through which the organization may acquire the selective worldwide rights to a MDM2 protein degrader created utilizing the Proteolysis-Targeting Chimeras (PROTACs) innovation. The medication competitor is ...

Read More

News-Medical.Net | March 02, 2020

news image

CHALLENGES FOR TRANSLATING PHARMACOMICROBIOMICS TO PERSONALIZED MEDICINE

A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.Pharmacomicrobiomics is the study of how microbiome variations within and between individuals affect drug action, efficacy, and toxicity. This personalized medicine horizon scanning is featured in OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. Ramy Aziz and Marwa ElRakaiby, Cairo Univer...

Read More